Xolair (omalizumab) is an injectable prescription medication used to treat moderate to severe persistent allergic asthma and chronic hives (a condition called chronic idiopathic urticaria, or CIU). However, health complications in patients necessitated two FDA-approved label changes to the drug; one for anaphylaxis, which can be life-threatening, and another describing a slightly higher risk of heart and brain blood vessel problems, such as mini-strokes, heart attacks, chest pain, high blood pressure in the arteries of the lungs and blood clots.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Xolair 150mg Box

Used to Treat: Moderate to severe persistent allergic asthma and chronic hives (chronic idiopathic urticaria – CIU)

Manufacturer: Genentech Inc. and Novartis Pharmaceuticals Corporation

Black Box Warnings: Anaphylaxis — a severe, potentially life-threatening allergic reaction

Active Ingredient: Omalizumab

FDA Approval: 2003

Xolair (omalizumab) is an injectable medication used to treat patients with a type of asthma caused by allergens (allergic asthma) and a chronic type of hives with no identifiable cause (chronic idiopathic urticaria). But the drug has been linked to severe, life-threatening allergic reactions called anaphylaxis and other possible side effects.

A black box warning was added to the drug’s label in 2007, advising patients and physicians that anaphylaxis could occur at any time after taking Xolair.

The U.S. Food and Drug Administration in 2009 began evaluating a study showing Xolair patients faced an increased risk of heart and brain blood-vessel problems.

The FDA said in 2014 it found evidence of blood-vessel risks but the study was flawed. That meant it could not “definitively confirm or determine the exact increased level of these risks.” The flaws also meant it couldn’t rule out the possibility of another potential side effect: Cancer.

The FDA initially approved the drug in 2003 for children 12 and older and adults. Novartis Pharmaceuticals Corporation and Genentech USA, Inc. announced in mid-2016 that the FDA had expanded Xolair users to include children as young as 6.

That made Xolair the first and only biologic for patients 6 and older with uncontrolled moderate to severe persistent allergic asthma.

What Does Xolair Treat?

Xolair treats moderate to severe persistent asthma from allergies (allergic asthma) for patients 6 and older whose symptoms cannot be adequately controlled with inhaled corticosteroids.

Having allergic asthma means symptoms are caused by allergens, substances that trigger immune-system responses. The immune system releases immunoglobulin E.

Normal Bronchial Tube
Inflamed Bronchial Tube
Normal vs. inflamed bronchiole tube

Too much immunoglobulin E can cause inflammation (swelling) in the body and in the airways in a person’s lungs. As the condition worsens, it can become difficult to breathe and may even result in an asthma attack.

Xolair blocks immunoglobulin E and may be a part of a treatment plan for people who suffer from allergic asthma.

What Is Asthma?

Asthma is a chronic disease that affects a person’s airways, causing them to swell, narrow and react strongly to allergens and other irritants. As the airways react and continue to narrow, less air can get through to your lungs.

Common asthma triggers include:

  • Animals (pet hair or dander)
  • Cockroaches
  • Changes in weather (usually colder temperatures)
  • Exercise
  • Pollen
  • Strong emotions or stress
  • Dust mites
  • Certain medications (such as aspirin and other NSAIDs)
  • Chemicals in the air or food
  • Mold
  • Respiratory infections (such as the common cold)
  • Tobacco smoke

Asthma can lead to symptoms such as wheezing (a whistling sound when you breathe), coughing (especially early in the morning or at night), chest tightness and shortness of breath. If symptoms of asthma worsen, it’s called an asthma attack. Severe asthma attacks may require emergency care and can even be life-threatening.

Asthma affects people of all ages, but it most often begins in childhood. In the United States, more than 25 million people are living with asthma, and approximately 7 million of those people are children. There is no cure for asthma, but it can be managed with quick-relief and long-term medications, and symptoms can sometimes improve over time.

What Is Chronic Idiopathic Urticaria (CIU)?

Chronic idiopathic urticaria is the most common type of chronic hives. Xolair treats this condition in patients 12 and older who have persistent symptoms despite using anti-allergy drugs such as H1-antihistamines, or histamine blockers.

Urticaria is the medical term for hives, which are red and often itchy, sometimes painful, bumps on the skin that are usually caused by an allergic reaction to a drug or food. During an allergic reaction, the body releases chemicals called histamines that can make the skin swell into hives. Hives can also be caused by other conditions such as infections, stress and certain autoimmune conditions.

Hives on Young Man's Chest
Urticaria — or hives — are considered chronic when the condition lasts for 6+ weeks

When hives last for six weeks or longer, the condition is considered chronic. In about three out of 10 cases, the cause of hives is known. But in seven out of 10 cases of chronic hives, a cause cannot be determined. This is diagnosed as chronic idiopathic urticaria (CIU), and it is the most common type of chronic hives, mostly occurring between the ages of 20 and 40. Women are more likely than men to have CIU, experiencing flares that last anywhere from one to five years or longer.

In rare cases, hives can cause swelling in a person’s airways making it difficult to breathe and requiring emergency treatment. If not immediately treated, this dangerous occurrence can even result in death.

How Is Xolair Administered?

Woman Injected with Shot
Xolair is administered via injection, as pictured above

Xolair is an injectable prescription medicine administered by a health provider in a health care setting. It is a subcutaneous injection, meaning it is given in the fatty layer of tissue just under the skin. Subcutaneous injection sites can include the upper arms, abdomen in the belly area and front of the thighs.

The National Institutes of Health (NIH) advises rotating injection sites to keep the skin healthy, as repeated injections in the same location can cause scarring and hardening of tissues that can interfere with subsequent administration and absorption of medication.

Dosing Information

Xolair is administered in dosages of 150 milligrams to 375 milligrams every two to four weeks. Levels of immunoglobulin E and body weight are used to determine dosing and frequency. A patient’s physician should periodically reassess the need for continued treatment based on the severity of the disease and overall management of asthma symptoms.

Doses should be adjusted for any significant changes in body weight when receiving Xolair for the treatment of allergic asthma.

When receiving Xolair for the treatment of allergic asthma, doses should be adjusted for any significant changes in body weight. Re-testing of immunoglobulin E (IgE) levels during treatment cannot be used as a guide for subsequent dose determinations and adjustments, due to the fact that total IgE levels are elevated as a result of treatment and will remain elevated for up to one year following the discontinuation of the asthma medication.

Dosing of Xolair in patients being treated for chronic idiopathic urticaria is not determined by IgE levels or body weight. Rather, treatments are administered by subcutaneous injection every four weeks in dosages of 150 milligrams or 300 milligrams. A patient’s physician should periodically reassess the need for continued treatment as the appropriate duration of Xolair therapy for chronic idiopathic urticaria has not yet been evaluated.

Xolair injections take approximately five to 10 seconds to administer due to the consistency of the solution being slightly viscous (thick and sticky). Each vial delivers 150 milligrams. If more than 150 milligrams is required, the doses need to be divided among two or more injection sites.


Studies have not yet determined the maximum tolerated dose of Xolair. When administering single doses of up to 4,000 milligrams to patients, no toxicity was found to have resulted. The highest cumulative dose administered to patients was 44,000 milligrams over a 20-week period with no adverse events or resulting toxicity associated with the higher dosing amount.

Side Effects of Xolair

Xolair is not without side effects, ranging from mild to severe, and even life-threatening. Anaphylaxis can occur after one dose or many doses. It can also occur immediately after receiving the injection or days later. If not immediately treated, anaphylaxis can be deadly. The FDA reviewed a study that found Xolair patients had a slightly increased risk of problems involving the heart and blood vessels in the brain.

These problems included:

  • Mini-strokes (known as transient ischemic attacks, or TIAs)
  • High blood pressure in the arteries of the lungs (called pulmonary hypertension)
  • Heart attacks
  • Sudden, unexpected chest pain
  • Blood clots in the lungs and veins

Other common side effects of Xolair include:

  • Pain, especially in the arms and legs
  • Feeling tired
  • Bone fractures
  • Dizziness
  • Skin rash
  • Pain or discomfort of the ears

Pediatric patients (ages six to 12) may experience slightly different side effects, including common cold symptoms, headache, fever, sore throat, earache or ear infection, abdominal pain, nausea, vomiting and nose bleeds.

Side effects in patients who are being treated for CIU:

  • Nausea
  • Swelling of the inside of your nose, throat or sinuses
  • Joint pain
  • Headaches
  • Cough
  • Upper respiratory tract infection

Injection site reactions include swelling, erythema (redness of the skin caused by increased blood flow in the capillaries in the lower layers of skin), pain, itching, bleeding and hives.

Serious side effects of Xolair include:

  • Cancer — Patients receiving Xolair may have a higher risk of certain types of cancer.
  • Inflammation of blood vessels — Symptoms include chest pain, shortness of breath, or a feeling of pins and needles or numbness of the arms and legs.
  • Fever, muscle aches and rash — These symptoms can occur one to five days after receiving Xolair.
  • Parasitic infection — This side effect can occur after receiving Xolair in patients who are at high-risk for parasite (worm) infections.
  • High blood levels of a certain antibody (serum total IgE)

Black Box Warning: Anaphylaxis

In July 2007, the U.S. Food and Drug Administration announced that Genentech updated its labeling for Xolair to include a black box warning. The FDA requested the change following new post-marketing reports that anaphylaxis was occurring after administration of the injectable asthma drug. In a news bulletin, the FDA said it requested the labeling change “because of the continued reports of anaphylaxis and the life-threatening potential of its delayed onset.”

According to the National Institutes of Health (NIH), anaphylaxis is “a severe, whole-body allergic reaction to a chemical that has become an allergen.” It is an emergency condition that requires immediate medical attention. Without treatment, anaphylaxis can result in blocked airways, cardiac arrest (stopping of the heart), respiratory arrest (no breathing) or shock.

Symptoms of an anaphylaxis reaction can include:

  • Trouble breathing
  • Chest tightness
  • Dizziness or lightheadedness
  • Nausea or vomiting
  • Difficulty swallowing
  • Fainting
  • Itching and hives
  • Swelling of the, face, eyes, mouth, tongue and throat
  • Abdominal pain
  • Feeling anxious
  • Diarrhea
  • Low blood pressure
  • Flushing or feeling warm
  • Unconsciousness
  • Palpitations
  • Slurred speech

In previous clinical trials for Xolair that included 39,500 human test subjects, it was determined that anaphylaxis occurred in as little as 0.1 percent of patients, typically within one to two hours of receiving a subcutaneous injection of the medication.

But new reports indicated that anaphylaxis was delayed in some patients, sometimes for more than 24 hours following a Xolair treatment. While this result can occur as early as after the first dose of Xolair, it was also found to occur after any dose of the asthma medication even beyond one year of beginning regular treatment on Xolair, and even if there was no adverse reaction to previous doses.

FDA Safety Communication: Risk for Heart and Brain Problems

In July 2009, the FDA announced it was evaluating a study that suggested an increased number of heart and brain complications and other potential adverse events in patients being treated with Xolair.
ABC News reported that the FDA began its review following reports of “an increased risk of heart attack, abnormal heart rhythm, heart failure and stroke.”

The study spanned five years. It included 5,000 Xolair users and a control group of 2,500 non-Xolair users. In September 2014, the FDA said the study showed a “slightly higher rate of heart and brain blood vessel problems” in the patients being treated with Xolair compared to those who were not treated. But the study was flawed, the agency said.

The FDA found that Xolair users were at a higher risk for heart problems compared to nonusers.

“Although the data are suggestive of a serious safety signal, due to weaknesses in how the safety study was designed and carried out, we are unable to definitively confirm or determine the exact increased level of these risks with Xolair,” FDA said.

The FDA furthered its evaluation by reviewing an analysis of 25 randomized, double-blind clinical trials comparing Xolair to a placebo. These trials did not come to the same conclusion. But FDA noted it could not reach “definite conclusions” about the absence of risk.

While the agency stopped short of requiring Genentech and Novartis to issue a black box warning, this new information did necessitate changes to the “Adverse Reactions” section of the drug label.

This new information prompted changes to the adverse reactions section of the drug label. The FDA also found no difference in cancer rates among Xolair users and nonusers. But the agency also said it could not rule out a potential risk of cancer. Therefore, the FDA required this information to also be added to the warnings and precautions section of the drug label.

Drug Interactions

Did You Know

No formal drug interaction studies have been performed with Xolair.

No formal drug interaction studies have been performed with Xolair. In patients with allergic asthma, the associated use of Xolair and allergen immunotherapy (commonly referred to as allergy shots) has not been evaluated. Similarly, it is unknown what interactions might occur in patients with CIU using Xolair and other immunosuppressive therapies simultaneously.

Adequate and well-controlled studies in pregnant women using Xolair have not been conducted, and therefore, the data is insufficient to inform patients on associated risk. Likewise, for breastfeeding mothers, it is unknown if Xolair is present in breast milk.

Xolair Lawsuits

In 2006, 2010 and 2012, Genentech and Novartis were hit with whistleblower lawsuits filed by Frank Garcia, Stephen Fauci and Allison Kelly, respectively, all former employees of the drug companies. Federal law allows whistleblowers to file suits on behalf of the government alleging fraud. If the government wins, whistleblowers receive a portion of the award.

Genentech, whose San Francisco headquarters is pictured above, was hit with whistleblower actions by former employees


In these suits, the whistleblowers alleged that Genentech and Novartis engaged in off-label marketing (including urging health care professionals to use Xolair for children, active asthma and other allergic conditions not related to asthma, such as peanut allergies), and kickback schemes in the form of free cash equivalents and expensive gifts, free medical and office equipment, and free services to health care providers to induce them to prescribe Xolair in an effort “to broaden their patient population and increase sales.” The whistleblowers claimed that the companies engaged in these actions despite the FDA’s approval for “limited uses.”

The whistleblowers also claimed that the drug companies’ efforts were successful, driving sales from $25 million in Xolair’s first year on the market to $320 million in just two years.

Plaintiffs claimed that the manufacturers misbranded Xolair, making it ineligible for reimbursement under government health care programs.

The whistleblowers further claimed that Genentech and Novartis had misbranded Xolair “making it ineligible for reimbursement” under government health care programs, such as Medicare and Medicaid. Additionally, the whistleblowers claimed that health care providers were induced to submit claims for reimbursement at improper rates by using improper medical codes for the administration of Xolair.

But on June 17, 2016, the U.S. Court of Appeals affirmed a district court’s ruling to dismiss the federal claims with prejudice (meaning they cannot be amended, revised and refiled). The court found the whistleblowers failed to make their complaints with “sufficient particularity” (not clearly enough).

However, the appeals court found a procedural error and sent that part back to the district court, providing the whistleblowers an opportunity to amend and refile those claims.

Potential for Personal Injury Claims

With former employees accusing Genentech and Novartis of wrongdoing in the marketing and sales of Xolair, and with post-marketing studies and reports linking the use of Xolair to serious

Future Claims Incoming

Drug companies are likely to face lawsuits stemming from personal injury claims made by injured patients using Xolair.

side effects, such as life-threatening anaphylaxis, heart attacks, mini-strokes, blood clots in the lungs, high blood pressure in the arteries of the lungs, and possibly even cancer, the drug companies are likely to face lawsuits stemming from personal injury claims made by injured patients using Xolair.

Law firms across the country are currently discussing legal options with injured consumers and preparing to file lawsuits on behalf of patients who have suffered serious side effects or even death after receiving Xolair treatments.


Kristin Compton is a medical writer with a background in legal studies. She has experience working in law firms as a paralegal and legal writer. She also has worked in journalism and marketing. She’s published numerous articles in a northwest Florida-based newspaper and lifestyle/entertainment magazine, as well as worked as a ghost writer on blog posts published online by a Central Florida law firm in the health law niche. As a patient herself, and an advocate, Kristin is passionate about “being a voice” for others.

Hide Sources

  1. "Genetech Headquarters" by Coolcaesar is licensed under CC BY-SA 3.0. Retrieved From: https://commons.wikimedia.org/wiki/File%3AGenentechheadquarters.jpg
  2. American College of Emergency Physicians (ACEP). (2007). FDA Wants Black Box Warning for Xolair. Retrieved from: https://www.acep.org/content.aspx?id=26520
  3. Asthma and Allergy Foundation of America (AAFA). (N.D.). Allergens and Allergic Asthma. Retrieved from: http://www.aafa.org/page/allergic-asthma.aspx
  4. FDA. (2009). Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair). Retrieved from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm
  5. FDA. (2014). Xolair: Full Prescribing Information. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5211lbl.pdf
  6. FDA. (2014). FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. Retrieved from: https://www.fda.gov/Drugs/DrugSafety/ucm414911.htm
  7. FDA. (2016). Medication Guide: Xolair. Retrieved from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM089829.pdf
  8. FDANews. (2007). Genentech Adds Black Box Warning to Xolair. Retrieved from: http://www.fdanews.com/articles/95475-genentech-adds-black-box-warning-to-xolair
  9. FDANews. (2014). FDA Requiring Cardiac and Cerebral Warnings on Genentech’s Xolair Label. Retrieved from: http://www.fdanews.com/articles/167502-fda-requiring-cardiac-and-cerebral-warnings-on-genentechs-xolair-label
  10. Genentech USA Inc. and Novartis Pharmaceuticals Corporation. (2017). What is chronic idiopathic urticaria (CIU)? Retrieved from: http://www.xolair.com/ciu/what-is-chronic-idiopathic-urticaria.html
  11. Genentech USA Inc. and Novartis Pharmaceuticals Corporation. (2017). Xolair: Important Safety Information. Retrieved from: http://www.xolair.com/allergic-asthma/hcp/safety-and-side-effects.html?cid=xol_PS_MIXLAAH8182_13&c=MIXLAAH8182
  12. Genentech USA Inc. and Novartis Pharmaceuticals Corporation. (2017). Xolair. Retrieved from: http://www.xolair.com/allergic-asthma/
  13. Legal Information Institute (LII). (N.D.). Qui tam action. Retrieved from: https://www.law.cornell.edu/wex/qui_tam_action
  14. MedlinePlus, NIH. (2015). Asthma. Retrieved from: https://medlineplus.gov/ency/article/000141.htm
  15. MedlinePlus, NIH. (2015). Subcutaneous (SQ) injections. Retrieved from: https://medlineplus.gov/ency/patientinstructions/000430.htm
  16. MedlinePlus, NIH. (2016). Anaphylaxis. Retrieved from: https://medlineplus.gov/ency/article/000844.htm
  17. MedlinePlus, NIH. (2016). Steroids. Retrieved from: https://medlineplus.gov/steroids.html
  18. MedlinePlus, NIH. (2017). Asthma. Retrieved from: https://medlineplus.gov/asthma.html
  19. MedlinePlus, NIH. (2017). Hives. Retrieved from: https://medlineplus.gov/hives.html
  20. Monroe, EW, Cohen, SH, Kalbfleisch, J. and Schulz, CI. (1981). Combined H1 and H2 antihistamine therapy in chronic urticaria. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/6114712
  21. More, MD, D. (2017). Common Causes of Hives. Retrieved from: https://www.verywell.com/what-are-the-common-causes-of-hives-82866
  22. NIH. (2014). What Is Asthma? Retrieved from: https://www.nhlbi.nih.gov/health/health-topics/topics/asthma
  23. NIH. (2016). NIH Clinical Center Patient Education Materials: Giving a Subcutaneous Injection. Retrieved from: https://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf
  24. Novartis Pharmaceuticals Corporation. (2016). Novartis announces FDA approval of Xolair (omalizumab) for pediatric allergic asthma. Retrieved from: https://www.pharma.us.novartis.com/news/media-releases/novartis-announces-fda-approval-xolairr-omalizumab-pediatric-allergic-asthma
  25. Reinberg, S. (2009). FDA Investigating Safety of Asthma Drug Xolair. Retrieved from: http://abcnews.go.com/Health/Healthday/story?id=8105117&page=1
  26. United States of America, et al., ex. rel. Frank Garcia, et al. v. Novartis AG, et al. (17 March 2015). Memorandum and Order.
  27. United States of America et al., ex. rel., Allison Kelly, Frank Garcia, et al. v. Novartis Pharmaceuticals Corporation, et al. (17 June 2016). Appeal From the United States District Court for the District of Massachusetts. Retrieved from: http://media.ca1.uscourts.gov/pdf.opinions/15-1470P-01A.pdf